Core Insights - The presentation focuses on the additional results from the Phase III VIKTORIA-1 clinical trial, specifically for the PIK3CA wild-type cohort, which were recently presented at the ESMO Congress in Berlin [1]. Group 1: Company Overview - Celcuity is led by CEO and Co-Founder Brian Sullivan, who is joined by Chief Medical Officer Dr. Igor Gorbatchevsky for the presentation [1]. Group 2: Clinical Trial Details - The VIKTORIA-1 trial is significant as it explores the PAM pathway, which is a crucial oncogenic pathway involving PI3K, AKT, and mTOR [3].